Rheos Medicines Appoints Industry Leader, John Davis, Jr., M.D., M.P.H., M.S., to Board of Directors
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Rheos Medicines, Inc., a biopharmaceutical company transforming the treatment of autoimmune disease through its metabolic precision medicine (MetPM) platform, today announced the appointment of John Davis, Jr., M.D., M.P.H., M.S. to its board of directors. Dr. Davis is an experienced physician-scientist drug developer and biotechnology executive with deep expertise across platforms, technologies and a range of therapeutic areas, including leadership roles at Pfizer, Baxalta, Magenta Therapeutics, and Genentech.
“We are pleased to welcome John to our board of directors,” said Barbara Fox, Ph.D., Chief Executive Officer of Rheos Medicines. “John brings extensive expertise in bridging translational research and designing and implementing clinical development programs to advance new medicines for autoimmune and inflammatory diseases, as well as the unique perspective of a physician-scientist who continues to work closely with patients suffering from these conditions. His breadth of experience will be invaluable as we prepare to advance our lead program into the clinic next year, and explore the full potential of our MetPM product engine to build a leading franchise of precision medicines for autoimmune and inflammatory diseases.”
In his most recent role, Dr. Davis serves as Chief Medical Officer and Head of Research and Development at Magenta Therapeutics, a biotechnology company bringing innovative therapies to the field of stem cell transplants for patients with autoimmune diseases, genetic diseases, and blood cancers. Prior to joining Magenta, Dr. Davis was Senior Vice President and Head of Early Clinical Development at Pfizer and, before that, he served as Vice President and Global Therapeutic Area Head of Immunology at Baxalta and as Senior Group Director and Head of the Inflammation and Cardiovascular/Metabolism Group in the Early Clinical Development Group at Genentech. Earlier, Dr. Davis spent nearly 10 years on the faculty at the University of California, San Francisco, leading clinical research in autoimmune diseases and serving as Professor of Clinical Medicine until 2015. He continues to see patients, teach, and serve as volunteer faculty at the Boston VA Medical Center. Dr. Davis holds his M.D. from the University of Maryland and completed his training in internal medicine and rheumatology at the University of California, San Francisco. He continued training in clinical research and rheumatology at the National Institutes of Health NIAMS intramural program. He holds an M.P.H. in Epidemiology from the University of California, Berkeley, and an M.S. in Anatomical Science from the University of Maryland School of Medicine. Dr. Davis is also a Fellow of the American College of Physicians and the American College of Rheumatology.
“I am excited to join Rheos’ board of directors and look forward to working with the company’s management team to advance their vision of delivering a new class of precision medicines to patients with immune-mediated diseases,” said Dr. Davis. “I believe Rheos’ platform, which combines a deep understanding of metabolic processes with analyses to identify drivers of disease heterogeneity among patient subpopulations, opens the potential to discover novel precision medicines for patients with autoimmune and inflammatory diseases.”
About Rheos Medicines
Rheos Medicines is a biopharmaceutical company harnessing insights in immunometabolism to develop novel therapeutics for patients with severe immune-mediated diseases. Our approach targets the underlying intracellular metabolism of immune cells and has the potential to unlock a new frontier in drug discovery for immune-mediated disease. Through a proprietary platform and product engine that integrates multiple “omic” datasets, we systematically define the biologic links between immune cell metabolism and function and simultaneously identify new drug targets and biomarkers of disease to bring precision to the treatment of immune-mediated diseases. We have assembled leading scientists whose discoveries opened the field of immunometabolism, clinicians with a deep understanding of immune-mediated diseases, and an experienced biotech leadership team. Rheos was founded by Third Rock Ventures and is located in Cambridge, MA. For more information, please visit www.rheosrx.com.
Source: Rheos Medicines